NEW YORK – Xi'an, China-based Yufan Biotechnologies and Pittsburgh-based Abound Bio announced on Wednesday that they had entered a three-year partnership to jointly develop CAR T-cell therapies directed at 10 different cancer targets.
NEW YORK – Xi'an, China-based Yufan Biotechnologies and Pittsburgh-based Abound Bio announced on Wednesday that they had entered a three-year partnership to jointly develop CAR T-cell therapies directed at 10 different cancer targets.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.